DR. FENGLIN CHEN – PATENTED MEDICAL SPECIALIST IN THE TREATMENT OF RECURRENT SPONTANEOUS ABORTIONS

DR. FENGLIN CHEN – PATENTED MEDICAL SPECIALIST IN THE TREATMENT OF RECURRENT SPONTANEOUS ABORTIONS
Sep
29
Posted by   FengLin ChenPosted in  Blog0This post is also available in: Chinese (Simplified), Chinese (Traditional)

DR. FENGLIN CHEN – PATENTED MEDICAL SPECIALIST IN THE TREATMENT OF RECURRENT SPONTANEOUS ABORTIONS

Overview of Recurrent Spontaneous Abortion

Habitual abortion, also known as recurrent spontaneous abortion (RSA), is the phenomenon in which spontaneous abortion or cessation of fetal development occurs repeatedly within a set time frame during gestation. RSA occurs with a rate of 1% of all pregnancies.  Habitual abortion is not an independent disease, but one with 43 known causes. Traditionally, classification and diagnosis of RSA both have been unclear, and no effective treatments were developed, posing a major problem in the field of professional medicine.

About Dr. Fenglin Chen

Dr. Fenglin Chen has dedicated his life to the research of RSA. He first performed scientific classification of RSA and studied its causes according to early, late, primary, and secondary properties, and found that immune factors accounted for 67% of all cases, anatomical factors accounted for 14%, endocrine factors accounted for 11%, and other factors accounted for 8% of all cases.

Dr. Chen then conducted research on the fundamental properties of autoimmune early secondary habitual abortion, the highest incident rate case of RSA, and found that the real cause is that intrauterine abortion and other similar operations can cause the body to produce anti-embryonic antibody. Based on his findings, Dr. Chen researched and developed a DNA vaccine which effectively treats early autoimmune habitual abortion; for cases of uterine septum, Dr. Chen developed anti-adhesion surgical techniques such as cold knife separation and pear-shaped support surgery; for variants of intrauterine adhesions he performs endometrial transplants; for cases of unicornuate uterus, he developed laparoscopic uterine fusion; for luteal phase defects, Dr. Chen developed a treatment of need-based luteolysis adjustments. Recently, Dr. Chen also developed the cervical isthmic cerclage technique to prevent late abortion caused by cervical relaxation, opening new possibilities in the study and treatment of miscarriages. Today, Dr. Chen possesses definitive and effective treatments for 92% of all habitual abortions.

In 2003, based on his technology and techniques, Dr. Chen financed  20 million RMB at the Shanghai Joint Ventures Investment Firm, and established Beijing Antai Medical Technology Service Co., Ltd, under which he established the Beijing Xinjing Antai Maternity Hospital (closed during relocation) and Antai Jiayuan Hospital. The name Antai comes from the Chinese translation of “protecting pregnancies”, and primarily treats various types of RSA. These hospitals are pioneers in serving patients with complete assurance, and offer contracts with a full money back guarantee should the final purposes of treatment be not met, completely changing the traditional principle of medical care. The hospitals receive annual profits of more than 20 million RMB. In all, Dr. Chen and his hospitals have treated nearly ten thousand cases of different types of RSA, and achieve a success rate as high as 98%.

Dr. Chen has patented his research and techniques on RSA under two separate patents: “Medicament and Method for Treating Recurrent Spontaneous Abortion” and “Methods for Diagnosing and for Monitoring the Treatment of Recurrent Spontaneous Abortion”. These patents were approved in China, the U.S., and the European Union, and received second place in the Beijing Science and Technology Progress Awards. Dr. Chen has also received much media coverage in China, including CCTV2’s “Healthy Way” program special feature “Immunotherapy of Habitual Abortion”, Shangdong Station Medical Program “The Great Doctor – Chen Fenglin”, Hubei Station’s special interview, and articles in the People’s Daily newspaper, the Technology Daily newspaper, and Life and Times newspaper. Websites containing information on Dr. Chen and his hospitals can be found at http://www.atfck.com and http://www.antaihospital.com.

In 2011, Dr. Chen established the subsidiary company to Antai, RSA Institute Inc., in the United States. The purpose of this company will be to further develop the patented technologies—the RSA-specific diagnostic kit and the extremely effective DNA vaccine treatment. Using the advanced technology and equipment found in the U.S., the company will aim to commercialize these patented technologies to make them more easily accessible to the public, therefore benefiting all of society.

Related Posts
2004-5-24-CCTV2-the Way to Health-Immunotherapy for Recurrent Spontaneous Abortion
Dr. Fenglin Chen,the International Famous Miscarriage Expert